# AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

Source: https://onco.cc/trials/nct05617755/  
OnCo record `nct05617755` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of AB-1015 run by Arsenal Biosciences, Inc., terminated.

## Summary

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer is a phase 1 interventional study registered as NCT05617755 by Arsenal Biosciences, Inc., with 19 participants enrolled, started 2022-11-29. Conditions recorded: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Genital Neoplasm, Female, Abdominal Neoplasm and Recurrence. Interventions recorded: AB-1015.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05617755
- Phase: 1
- Setting: An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients With Resistant/Refractory Epithelial Ovarian Cancer
- Sponsor: Arsenal Biosciences, Inc.
- Enrolled: 19

## Sources

- ClinicalTrials.gov NCT05617755: https://clinicaltrials.gov/study/NCT05617755

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [AB-1015](https://onco.cc/drugs/ab-1015/)
- companies: [Arsenal Biosciences](https://onco.cc/companies/arsenal-bio/)

---
JSON: https://onco.cc/api/v1/entities/nct05617755.json